Researchers reported a dextran‑based nanoparticle system that enhances CAR‑T cell production by improving transduction efficiency and cell expansion during manufacturing. The platform aims to lower costs and boost yield for autologous CAR‑T therapies by streamlining key ex vivo steps, potentially shortening production timelines and increasing product consistency for hematologic and solid‑tumor CAR‑T programs. The study included in vitro and preclinical validation of phenotype and function for CAR‑T cells produced with the dextran nanoparticles; translational challenges noted include GMP‑compatible synthesis, scalability, regulatory comparability testing, and ensuring the absence of residual nanoparticle effects in the final product.